Oral Antibiotics for Pseudomonas Infection

First-Line Oral Options

• The European Respiratory Society recommends ciprofloxacin as the primary oral agent with reliable antipseudomonal activity, with dosages ranging from 500-750 mg PO twice daily 2
• Ciprofloxacin is the preferred oral antibiotic for treating Pseudomonas aeruginosa infections, with dosing typically 500-750 mg twice daily depending on infection severity and site 1

Clinical Considerations

• The Journal of Microbiology, Immunology and Infection suggests that the choice of oral therapy should be guided by susceptibility testing whenever possible, as resistance to fluoroquinolones can develop 3
• The European Respiratory Journal recommends that for serious Pseudomonas infections, initial intravenous therapy followed by oral step-down therapy may be more appropriate than oral therapy alone 2
• The Journal of Microbiology, Immunology and Infection recommends that treatment duration should be individualized according to infection site, source control, underlying comorbidities, and initial response to therapy 3

Special Populations

• The Journal of Microbiology, Immunology and Infection and Pediatrics recommend that in pediatric patients, ciprofloxacin can be used at 10-20 mg/kg/dose PO every 12 hours (maximum 750 mg/dose) when benefits outweigh risks 3, 5
• The European Respiratory Journal suggests that for cystic fibrosis patients with Pseudomonas infections, oral ciprofloxacin is sometimes used as maintenance therapy or for mild exacerbations 4

Resistance Concerns

• The American College of Clinical Pharmacy and Praxis Medical Insights recommend that in patients who have received fluoroquinolones within the past 90 days, consider alternative agents or combination therapy due to increased risk of resistance 1

Common Pitfalls

• The Clinical Infectious Diseases journal recommends that for serious infections, combination therapy with an antipseudomonal β-lactam plus either ciprofloxacin or an aminoglycoside is often recommended initially 6
• The Infectious Diseases Society of America and Praxis Medical Insights warn that monotherapy with oral agents may be insufficient for severe Pseudomonas infections such as pneumonia, osteomyelitis, or bacteremia 6, 1

Alternative Approaches

• The Journal of Microbiology, Immunology and Infection recommends that in cases of multidrug-resistant Pseudomonas, combination therapy and consultation with an infectious disease specialist is recommended 3
• The American College of Clinical Pharmacy and Praxis Medical Insights suggest that for patients with contraindications to fluoroquinolones, parenteral therapy with antipseudomonal β-lactams, aminoglycosides, or polymyxins may be necessary 1